Clinical Remissions In Three Otherwise Intractable Cancers Signal The ...
Oct 13, 2009 | Posted by: roboblogger | Full story: MediLexicon
Epeius Biotechnologies Corporation announced more stunning results of its pioneering clinical studies of Rexin-G, the world's first and, so far only, tumor-targeted genetic medicine to be validated in the clinic.
|FDA Approves Cometriq (cabozantinib) to Treat R... (Nov '12)||Feb 26||Joe||6|
|Personalized Therapy Feasible for Metastatic Br...||Feb 10||SANDY SMIITH||1|
|Preparing for Breast Reconstruction After Breas...||Feb 9||Lindsay||1|
|Antidepressant Doxepin Relieves Pain Associated... (Dec '12)||Jan '14||Delaney||3|
|Breast-Conserving Surgery Leaves Many Cancer Pa... (Jul '08)||Jan '14||Jorry||7|
|Psychological challenges of surviving cancer (Dec '08)||Jan '14||Paola||3|
|Bath Chronicle published Treatment offered for ... (Apr '13)||Jan '14||Berke||2|